The dysregulation of postprandial lipid metabolism in insulin resistant states and subsequent CVD risk, the clinical evaluation of postprandial dyslipidemia, present research constraints, and potential subsequent study directions round up the narrative. This evidence concerns the gene INS and metabolic syndrome.